CRP and type 2 diabetes mellitus: Furthermore, omentin-1 treatment significantly improved the pro-inflammatory and pro-oxidant PVAT phenotype (i.e., through reduction of C-reactive protein and nitrotyrosine levels), suggesting that omentin-1 could improve endothelial dysfunction in T2DM patients by improving dysfunction PVAT; it also has the potential to treat T2DM-related vascular complications (28).